Literature DB >> 19162574

Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis?

M Merli1, F Gentili, M Giusto, A F Attili, S G Corradini, G Mennini, M Rossi, A Corsi, P Bianco.   

Abstract

BACKGROUND: The recurrence of hepatitis C after liver transplantation is extremely frequent. Antiviral therapy combining pegylated-interferon with ribavirin is therefore increasingly used in these patients. It has been recently reported, however, that during antiviral treatment a hepatic immune-mediated liver dysfunction, similar to "de novo" autoimmune hepatitis, may develop in a few transplanted patients. PATIENTS AND METHODS: Three patients, treated with pegylated-interferon alpha-2a and ribavirin for recurrent hepatitis C after liver transplantation, developed an aggressive hepatitis with clinical, biochemical, and histological features similar to those of autoimmune hepatitis.
RESULTS: In all three patients, a liver enzymes increase was evident after hepatitis C virus-RNA had become undetectable. Diagnosis of "de novo" autoimmune hepatitis was proposed, based on the presence of high-titre circulating autoantibodies and liver histology features. Following the introduction of a steroid therapy, clinical and biochemical parameters progressively improved. Hepatitis C virus infection, however, relapsed after a few months in all the patients.
CONCLUSIONS: Following liver transplantation, antiviral therapy with pegylated-interferon alpha-2a and ribavirin for recurrent hepatitis C may be associated, in a few patients, with severe immune-mediated graft dysfunction similar to autoimmune hepatitis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19162574     DOI: 10.1016/j.dld.2008.09.015

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  7 in total

1.  The prediction of immunological dysfunction during antiviral therapy for HCV after liver transplantation: can we improve outcomes?

Authors:  Ji-Yuan Zhang; Yuan-Yuan Li; Zheng Zhang; Fu-Sheng Wang
Journal:  Hepatol Int       Date:  2013-10-17       Impact factor: 6.047

2.  Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival.

Authors:  Pratima Sharma; Amy Hosmer; Henry Appelman; Barbara McKenna; Mohammad S Jafri; Patricia Sullivan; Robert J Fontana; Anna S Lok
Journal:  Hepatol Int       Date:  2013-10       Impact factor: 6.047

Review 3.  De novo autoimmune hepatitis in liver transplant: State-of-the-art review.

Authors:  Ranka Vukotic; Giovanni Vitale; Antonia D'Errico-Grigioni; Luigi Muratori; Pietro Andreone
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

4.  De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: report of a case.

Authors:  Kazuki Takeishi; Ken Shirabe; Takeo Toshima; Toru Ikegami; Kazutoyo Morita; Takasuke Fukuhara; Takashi Motomura; Yohei Mano; Hideaki Uchiyama; Yuji Soejima; Akinobu Taketomi; Yoshihiko Maehara
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

5.  Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C.

Authors:  Toru Ikegami; Huanlin Wang; Tomoharu Yoshizumi; Takeo Toshima; Shinichi Aishima; Takasuke Fukuhara; Norihiro Furusyo; Kazuhiro Kotoh; Shinji Shimoda; Ken Shirabe; Yoshihiko Maehara
Journal:  Hepatol Int       Date:  2013-12-27       Impact factor: 6.047

6.  Infiltrative (sinusoidal) and hepatitic patterns of injury in acute cellular rejection in liver allograft with clinical implications.

Authors:  Iram Siddiqui; Nazia Selzner; Sara Hafezi-Bakhtiari; Max A Marquez; Oyedele A Adeyi
Journal:  Mod Pathol       Date:  2015-07-31       Impact factor: 7.842

7.  Concurrent autoimmune hepatitis and grave's disease in hepatitis C during pegylated interferon α-2a and ribavirin therapy.

Authors:  Guru V Trikudanathan; Imad Ahmad; Jonathan L Israel
Journal:  Saudi J Gastroenterol       Date:  2011 Sep-Oct       Impact factor: 2.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.